Pfizer Chairman and CEO Albert Bourla says the corporate remains to be available in the market for acquisitions following its $43 billion acquisition of most cancers biotech agency Seagen Inc., however 2024 won’t see any main M&A exercise from the corporate. He speaks with David Westin on “Wall Avenue Week Each day.”
——–
Comply with Bloomberg for enterprise information & evaluation, up-to-the-minute market knowledge, options, profiles and extra: http://www.bloomberg.com
Join with us on…
Twitter: https://twitter.com/enterprise
Fb: https://www.fb.com/bloombergbusiness
Instagram: https://www.instagram.com/bloombergbusiness/
